La catena delle opzioni mostra i dati chiave delle opzioni azionarie di RLX Technology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per RLX Technology..

RLX Technology (NYSE:RLX) Azioni, Catena delle Opzioni

RLX Technology

RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.

UltaBeautyGreenwood,,Indiana, - ,United,States,-,June,16,2020:,Beauty

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

DOCU

ULTA

Analisi pre-market svela opportunità nascoste nel mercato azionario: quali settori guideranno la crescita odierna? Occasione da non perdere.

Wall Street ottimista: questi 5 titoli potrebbero esplodere oggi

RLX Technology Inc. American Depositary Shares, each representing the right to receive one (1) Class A ordinary share

RLX Technology Inc

RELX PLC

The White House pushed back on criticism of its flagship domestic policy bill on June 2, <a href="https://www.whitehouse.gov/articles/2025/06/mythbuster-no-people-will-not-literally-die-with-the-one-big-beautiful-bill/">releasing an article</a> on its website titled, &#8220;MYTHBUSTER: No, People Will Not &#8216;Literally Die&#8217; With the One Big Beautiful Bill.&#8221; Officials claim the sweeping legislation strengthens Medicaid and helps low-income Americans by reducing fraud and encouraging work, in the piece.
<h2 class="wp-block-heading">White House Says Medicaid Will Be Stronger, Not Weaker</h2>
&#8220;This is one of Democrats' most disgusting lies,&#8221; the article said, claiming that the bill is designed to help pregnant women, children, people with disabilities, and low-income seniors. The administration said the bill will remove at least <a href="https://www.benzinga.com/personal-finance/25/04/44789245/1-4-million-migrants-with-deportation-orders-could-be-facing-daily-fines-of-998-if-they-dont-leave-the-u-s">1.4 million undocumented immigrants</a> from Medicaid and end taxpayer-funded gender transition procedures for minors. It also aims to eliminate &#8220;waste, fraud and abuse&#8221; from the system.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
The White House also defended the bill&#8217;s work requirements for Medicaid recipients. &#8220;4.8 million able-bodied adults on Medicaid are choosing not to work,&#8221; the article claimed. The bill would require those recipients to participate in work, training, education or volunteering programs.
&#8220;Through work, job training, or part-time volunteering, this requirement will strengthen the system to better help those most in need of assistance,&#8221; the article continued. The administration said these types of requirements are not new and were once supported by former President Joe Biden.
<h2 class="wp-block-heading">Fact-Checkers Say the Cuts Go Far Beyond Waste</h2>
But a <a href="https://www.nytimes.com/2025/06/02/us/politics/trump-big-beautiful-bill-facts.html">New York Times</a> fact check disputed many of the administration&#8217;s claims. Citing a preliminary Congressional Budget Office <a href="https://d1dth6e84htgma.cloudfront.net/E_and_C_Markup_Subtitle_D_Part_I_5_12_25_4628d60c2a.pdf">estimate</a>, the Times reported that the bill would reduce federal Medicaid spending by at least $600 billion over a decade and cut enrollment by over 10 million people.
&#8220;These are cuts that will take away coverage and access from many millions of low-income Medicaid beneficiaries,&#8221; Medicaid expert and Georgetown University professor Edwin Park told the Times.&nbsp;
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
The Times reported that only a small portion of the changes qualify as targeting waste or fraud. Most provisions, it said, involve limiting access to care, imposing mandatory co-payments, reducing retroactive payments, and rolling back protections on medical debt. The largest savings, estimated at $280 billion, come from requiring Medicaid recipients to prove they work.
While the White House argues work requirements promote self-sufficiency, critics say they make it harder for eligible people to get coverage. The Times reported that most adult Medicaid recipients already work and that similar pilot programs in the past have not increased employment but have caused coverage losses.
<h2 class="wp-block-heading">Dispute Over The Deficit Impact</h2>
White House press secretary Karoline Leavitt also <a href="https://www.benzinga.com/news/politics/25/06/45764422/white-house-says-trump-is-sticking-to-the-big-beautiful-bill-despite-elon-musks-sharp-criticism-it-doesnt-change-the-presidents-opinion">claimed the bill</a> would save $1.6 trillion and bring about the largest deficit reduction in decades. But the CBO and several independent analyses found the opposite.
The CBO <a href="https://www.cbo.gov/system/files/2025-05/61422-Reconciliation-Distributional-Analysis.pdf">projected</a> the bill would increase the federal deficit by $3.8 trillion. Other estimates range from $1.7 trillion to $3.1 trillion in added debt.
See Also: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
<h2 class="wp-block-heading">Misleading Claims On Immigrants In Medicaid</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Speaker Johnson Sets The Record Straight On Medicaid &quot;We are not cutting Medicaid in this package. There&#39;s a lot of misinformation out there about this, Jake. The numbers of Americans who are affected are those that are entwined in our work to eliminate fraud, waste and abuse.&quot;… <a href="https://t.co/7iXBKLzgsJ">pic.twitter.com/7iXBKLzgsJ</a>
&mdash; Mr Producer (@RichSementa) <a href="https://twitter.com/RichSementa/status/1926693855325286627?ref_src=twsrc%5Etfw">May 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Both The White House article and Speaker Mike Johnson claim there are more than 1.4 million illegal aliens on Medicaid. But, according to the Times, this is false. Undocumented immigrants are not eligible for federally funded Medicaid except in emergencies, and states are required to verify immigration status. Some states do offer Medicaid-equivalent programs using their own funds, especially for children or pregnant women.
The bill would penalize those 14 states and Washington, D.C., by reducing their federal Medicaid funding, potentially leaving 7.6 million people uninsured.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

The White House Pushes Back With A 'Mythbuster' Article Saying People Won't 'Literally Die' From Their Tax Bill

WIIM

Lands' End shares are trading higher. The company reported Q1 financial results.

&nbsp;M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) and the Galesi Group have launched a major partnership that will expand their collaborative efforts to accelerate and sustain the revitalization of Schenectady's Mohawk Harbor. Under their agreement, M&amp;T Bank has secured the exclusive naming rights to the new state-of the-art events venue that Galesi Group is building in the heart of Mohawk Harbor.

M&T Bank, Galesi Group Forge Expanded Partnership To Fuel Mohawk Harbor's Emergence As Entertainment Destination

Optical Cable Corporation shares are trading lower. The company reported Q2 financial results.

Tempest Therapeutics, Inc. - Common Stock

TPST

Tempest Therapeutics shares are trading higher after the company announced it received orphan drug designation from the EMA for its amezalpat for the treatment of patients with hepatocellular carcinoma

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling around 0.1% points on Thursday.
The Dow traded down 0.06% to 42,400.42 while the NASDAQ fell 0.40% to 19,381.93. The S&amp;P 500 also fell, dropping, 0.27% to 5,954.96.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45744658/jim-cramer-recommends-nvidia-over-very-cheap-semiconductor-stock">Jim Cramer Recommends Nvidia Over &#8216;Very Cheap&#8217; Semiconductor Stock</a>
Leading and Lagging Sectors Communication services shares jumped by 0.4% on Thursday.
In trading on Thursday, consumer discretionary stocks fell by 1.5%.
Top Headline
Ciena Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) reported downbeat earnings for its fiscal second quarter.
The Hanover, Maryland-based company reported a quarterly revenue growth of 23.6% year-on-year to $1.13 billion, beating the analyst consensus estimate of $1.09 billion. The American telecommunications networking equipment and software services supplier reported adjusted EPS of 42 cents, missed the analyst consensus estimate of 52 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Planet Labs PBC &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) shares shot up 51% to $6.03 following a first-quarter sales beat and after the company raised its FY26 sales guidance</li>
<li>Shares of Liminatus Pharma, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) got a boost, surging 64% to $20.86 after the company announced it regained Nasdaq compliance.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares were also up, gaining 17% to $7.78 after the company announced it terminated its Rotech Healthcare acquisition.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) shares dropped 23% to $0.6829 following a first-quarter sales miss and after the company issued second-quarter sales guidance below estimates.</li>
<li>Shares of REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) were down 16% to $8.49 after the company announced new functional data from PHASE I/II Affinity Duchenne&#xAE; trial of RGX-202.</li>
<li>PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) was down, falling 17% to $66.92 after the company cut its FY25 guidance below estimates and issued second-quarter adjusted EPS guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $63.34 while gold traded down 0.8% at $3,373.80.
Silver traded up 3.1% to $35.735 on Thursday, while copper rose 0.7% to $4.9215.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.16%, while Spain's IBEX 35 Index rose 0.73%. London's FTSE 100 rose 0.11%, Germany's DAX 40 gained 0.19% and France's CAC 40 fell 0.18% during the session.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei falling 0.51%, Hong Kong's Hang Seng Index jumping 1.07%, China's Shanghai Composite gaining 0.23% and India's BSE Sensex gaining 0.55%.
Economics
<ul class="wp-block-list">
<li>Imports of goods and services into the US fell 16.3% to $351 billion during April.</li>
<li>Unit labour costs in the US nonfarm business sector rose 6.6% during the first quarter.</li>
<li>Exports of goods and services climbed 3% to $289.4 billion in April.</li>
<li>Nonfarm business sector labor productivity in the U.S. declined by 1.5% in the first quarter.</li>
<li>The U.S. trade gap shrank to $61.6 billion in April, recording the lowest level since September 2023.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45790413/lululemon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2">Lululemon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo via Shutterstock

Price Target

Analyst Ratings

CHPT

CIEN

LIMN

RGNX

Crude Oil Moves Higher; Ciena Posts Downbeat Earnings

MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) on Thursday revealed updated data from its THIO-101 pivotal <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45790333/maia-biotechnology-announces-positive-efficacy-update-for-phase-2-thio-101-clinical-trial-in-non-s" rel="noreferrer noopener">Phase 2 clinical trial</a>.
The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">therapy and chemotherapy</a>.
As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis demonstrates a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39909095/maia-biotechnologys-lung-cancer-drug-shows-promising-long-term-benefits-in-advanced-patients" rel="noreferrer noopener">MAIA Biotechnology&#8217;s Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients</a>
The treatment has been generally well-tolerated to date in this heavily pretreated population.
At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival.
Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.
&#8220;This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in the medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape,&#8221; said MAIA Chairman and CEO Vlad Vitoc.
MAIA&#8217;s multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.
The company announced a new partial response (PR) was identified in a patient after 20 months of treatment. A partial response is defined as a decrease in tumor size of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45796236/maia-biotechnology-announces-new-responder-in-non-small-cell-lung-cancer-phase-2-clinical-trial" rel="noreferrer noopener">at least 30%</a>.
&#8220;The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment,&#8221; Vitoc added.
Price Action: MAIA stock is up 11.7% at $1.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

MAIA

REGN

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

ImmunoPrecise Antibodies shares are trading higher after the company announced it discovered a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai platform

DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) will release its first-quarter earnings results after the <a href="https://www.benzinga.com/quote/DOCU/earnings">closing bell on Thursday, June 5</a>.
Analysts expect the San Francisco, California-based company to report quarterly earnings at 81 cents per share, down from 82 cents per share in the year-ago period. DocuSign projects to report quarterly revenue at $748.92 million, compared to $709.64 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 29, Docusign named Michael Adams as new Chief Information Security Officer.
DocuSign shares rose 2.4% to close at $93.84 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/docu/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>JMP Securities analyst Patrick Walravens reiterated a Market Outperform rating with a price target of $124 on June 3, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Karl Keirstead maintained a Neutral rating and cut the price target from $90 to $85 on April 17, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Morgan Stanley analyst Josh Baer maintained an Equal-Weight rating and cut the price target from $97 to $92 on April 16, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Jefferies analyst Brent Thill maintained a Buy rating and slashed the price target from $115 to $105 on March 31, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Citigroup analyst Tyler Radke maintained a Buy rating and raised the price target from $113 to $115 on March 14, 2025. This analyst has an accuracy rate of 71%.</li>
</ul>
Considering buying DOCU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/docu/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-1024x593.png" alt="" class="wp-image-938974" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04210406/image-59.png 1091w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45767953/jim-cramer-arrowhead-pharmaceuticals-doesnt-have-the-horses">Jim Cramer: Arrowhead Pharmaceuticals Doesn&#8217;t &#8216;Have The Horses&#8217;</a> </li>
</ul>
Photo via Shutterstock

DocuSign Likely To Report Higher Q1 Revenue; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

A friendship between President Donald Trump and billionaire Elon Musk may be coming to an end, with a heated <a href="https://www.benzinga.com/news/25/05/45635854/elon-musk-disappointed-with-trumps-big-beautiful-bill-says-it-undermines-the-work-that-the-doge-team-is-doing">public falling out</a> due to the "big beautiful bill."
What Happened: Musk helped the White House administration in the Department of Government Efficiency and was a close ally of Trump during his first 100+ days in<a href="https://www.benzinga.com/news/25/05/45707423/trump-says-he-is-having-elon-musk-over-at-the-white-house-tomorrow-for-a-press-conference-as-billion"> the White House.</a>
The billionaire, who is the world's richest man, publicly endorsed Trump for the 2024 presidential election and donated hundreds of millions to the campaign to get him elected.
The public friendship may now be coming apart, as Musk has vocally opposed the "Big Beautiful Bill," which would increase government spending and debt.
On Thursday, Trump said Musk isn't the first admirer to later turn on him. "It's sorta Trump Derangement Syndrome, they call it," the president said.
Trump said that sometimes people wake up, change their minds, and become hostile toward him.
&#8220;I'm very disappointed because Elon knew the inner workings of this bill better than almost anybody sitting here&#8230; He had no problem with it, all of the sudden he had a problem, and he only developed a problem when he found out that we&#8217;re going to have to cut the EV mandate.&#8221; 
Trump said while Musk hasn't said anything bad about him personally, he thinks that could be next.
"I'm very disappointed in Elon."
Trump added that the EV mandate would provide money to help the sector, which is "having a hard time." The president also said Musk wanted someone "he knew very well" to head NASA, a likely reference to Jared Isaacman, who Trump recently withdrew as the NASA administrator nominee.
Musk took to social media platform X to share his side of the story.
"False, this bill was never shown to me even once and was passed in the dead of night so fast that almost no one in Congress could even read it!" Musk <a href="https://x.com/elonmusk/status/1930662301792977094">tweeted</a>.
Another <a href="https://x.com/elonmusk/status/1930660788739698878">tweet </a>from Musk encouraged Congress to "ditch the mountain of disgusting pork in the bill."
"Either you get a big and ugly bill or a slim and beautiful bill. Slim and beautiful is the way."
Musk also said "whatever" to the EV incentive cuts and said the cuts could be kept in the bill even though oil and gas subsidies weren't cut.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45710022/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-67">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: The latest comments from Trump and Musk come after Musk shared several old tweets from the president on X that could be shading him over his support for the "Big Beautiful Bill."
Musk <a href="https://x.com/elonmusk/status/1930645855285231914">shared </a>an old 2013 tweet of Trump's that read, "I cannot believe the Republicans are extending the debt ceiling – I am a Republican &amp; I am embarrassed."
Musk also <a href="https://x.com/elonmusk/status/1930652448726925524">shared </a>an old 2012 tweet from Trump that said, "No member of Congress should be eligible for re-election if our country's budget is not balanced – deficits not allowed."
The new bill, which is in the Senate and could have changes made, is estimated to add $5 trillion to the national debt in the coming years based on estimates from the Congressional Budget Office.
Things may have escalated further on Thursday when Musk responded to a post in which Trump claimed he would have won the key swing state of Pennsylvania without the billionaire's help.
Musk thinks this is the opposite.
"Without me, Trump would have lost the election, Dems would control the House and the Republicans would be 51-49 in the Senate. Such ingratitude," Musk <a href="https://x.com/elonmusk/status/1930667528696828120">tweeted</a>.
Trump's comments on Thursday suggest the friendship could be over.
"Elon and I had a great relationship. I don't know if we will anymore," Trump said.
TSLA Price Action: Electric vehicle company Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has had <a href="https://www.benzinga.com/25/05/45475999/if-you-invested-1000-in-tesla-stock-when-elon-musk-endorsed-donald-trump-for-president-heres-how-much-youd-have-today">a bumpy road</a> for its stock price with Musk's relationship with the president. The stock soared after Trump's win and fell in 2025 with brand damage done and protests hitting the company and dealerships over Musk's political interests.
Tesla stock fell after Trump's comments Thursday and shares are down 7% to $308.78 at the time of writing. Tesla stock is down 18.8% year-to-date in 2025 with shares down over 13% in the last five days. &nbsp;
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45795080/whatever-you-think-of-elon-musk-you-must-support-his-fight-against-the-big-beautiful-bill-says-black-swan-author-nassim-taleb">&#8216;Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,&#8217; Says &#8216;Black Swan&#8217; Author Nassim Taleb</a></li>
</ul>
Photo: Shutterstock

Politics

TSLA

Trump Says Musk Has 'Trump Derangement Syndrome' As Battle Over Bill Heats Up: 'Had A Great Relationship… Don't Know If We Will Anymore'

Rumors

Nippon Steel Deal For U.S. Steel Seen Closing By Merger Deadline

<a href="https://aws.amazon.com/blogs/aws/announcing-up-to-45-price-reduction-for-amazon-ec2-nvidia-gpu-accelerated-instances/" title="https://aws.amazon.com/blogs/aws/announcing-up-to-45-price-reduction-for-amazon-ec2-nvidia-gpu-accelerated-instances/">https://aws.amazon.com/blogs/aws/announcing-up-to-45-price-reduction-for-amazon-ec2-nvidia-gpu-accelerated-instances/</a>

AMZN

NVDA

AWS Announces Up To 45% Price Reduction For Amazon EC2 NVIDIA GPU-Accelerated Instances

Rocket Companies, Inc. (NYSE:&nbsp;RKT) (the "Company" or "Rocket Companies"), the Detroit-based fintech platform including mortgage, real estate, title and personal finance businesses, today priced its private offering of $2.0 billion aggregate principal amount of 6.125% senior notes due 2030 and $2.0 billion aggregate principal amount of 6.375% senior notes due 2033 (collectively, the "Notes" and such offering, the "Offering").
The Offering is expected to close on June 20, 2025, subject to certain customary conditions.
The Company intends to use the proceeds from the Offering to (i) on the closing date for the Mr. Cooper Acquisition, redeem NMH's 5.000% senior notes due 2026, 6.000% senior notes due 2027 and 5.500% senior notes due 2028 at redemption prices equal to 100% of the principal amount of such notes, plus accrued and unpaid interest to, but excluding, the redemption date (the "Redemption"), (ii) pay fees and expenses related to the Offering and the Redemption, (iii) at the Company's discretion, redeem, purchase (including, if required, in a change of control offer) and/or amend NMH's 6.500% senior notes due 2029, 5.125% senior notes due 2030, 5.750% senior notes due 2031 and 7.125% senior notes due 2032 and pay fees and expenses in connection therewith and (iv) after the consummation of the Mr. Cooper Acquisition, repay secured debt of the Company and its subsidiaries (including Redfin, Mr. Cooper and their subsidiaries).

Rocket Companies Prices $4B Private Offering Of Senior Notes: $2B At 6.125% Due 2030, $2B At 6.375% Due 2033

CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading sideways on Thursday. But over the past week, <a href="https://www.benzinga.com/markets/equities/25/06/45793442/crowdstrike-ceo-defends-financial-reporting-amid-doj-probe-into-global-it-outage-says-we-stand-by-the-accounting-of-those-transactions">the shares have been extremely volatile</a>. 
Despite this, the stock demonstrated a principle of technical analysis. This is why our technical analysis team has made it our Stock of the Day.
The best traders can identify important price levels in markets. These levels are called support and resistance.
If a stock is trending lower, it is because there isn't enough demand to absorb all of the supply. There are more shares for sale than there are to be bought. This forces sellers to be aggressive and undercut each other's prices and it puts the shares into a downtrend.
At a support level, there is enough demand to absorb all of the supply. This is why sell-offs end or pause when they reach support.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-1024x571.png" alt="" class="wp-image-940172" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05140149/CrowdStrike.june2025.one_.png 1474w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/commodities/25/06/45792880/silver-hits-12-year-high-peter-schiff-says-rallys-just-starting">Silver Hits 12-Year High: Peter Schiff Says Rally&#8217;s Just Starting</a>
If a stock is moving higher, it&#8217;s because there is more demand than supply. There are more shares to be bought than there are for sale. Buyers are forced to cut in front of each other and outbid each other if they wish to acquire shares. This makes the stock move higher.
In the markets, what had been resistance can turn into support. This is a common occurrence and can be seen on the CrowdStrike chart.
Yesterday, the stock dropped to around $445. This was the low of the day and it was where there was support. There was support here because the level had been resistance.
Some of the people who sold around $445 regretted doing so after the resistance broke. Many decided to buy their shares back at their selling prices yesterday when CrowdStrike dropped to this level. This formed support.
Now there is support for the shares around $456. This can also be seen on the chart. This level had also been resistance.
In the financial markets, certain price levels have more importance than others. Good traders know how to identify them. This gives them an indication of where a trend may reverse.
Read Next: • <a href="https://www.benzinga.com/markets/market-summary/25/06/45798808/trump-announces-china-trade-talks-tesla-stock-slumps-whats-driving-markets-thursday">Trump Announces China Trade Talks, Tesla Stock Slumps: What&#8217;s Driving Markets Thursday?</a>
Photo: Shutterstock

Technicals

CRWD

Stock Of The Day: Where Is The Bottom In CrowdStrke?

<a href="https://www.philadelphiafed.org/the-economy/monetary-policy/250605-economic-outlook-and-final-thoughts">https://www.philadelphiafed.org/the-economy/monetary-policy/250605-economic-outlook-and-final-thoughts</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Harker Says Estimating Tariff Impact Is A Moving Target; Businesses Community Mainly Wants Stability In Trade Policy At This Point; Fed Faces No Rush To Shrink Size Of Balance Sheet

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

CLOV

EHTH

ELEV

GOCO

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) made a powerful entrance onto the New York Stock Exchange on Thursday, with shares of the stablecoin issuer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) opening at $69, more than double <a href="https://www.benzinga.com/markets/offerings/25/06/45785682/chamath-palihapitiya-says-circle-ipo-valued-at-7-billion-means-its-a-genius-buy-for-coinbase-heres-why">its $31 IPO price</a>.
The company raised approximately $1.1 billion through the sale of 34 million shares, securing a valuation of $6.9 billion and marking a major milestone after a previously unsuccessful public listing attempt via SPAC in 2021.
The timing of Circle's debut comes amid broader market uncertainty. 
As earnings season concludes, a majority of companies have offered cautious guidance, suggesting continued pressure on U.S. equities in the near term. 
Despite that backdrop, Circle&#8217;s business model has positioned it to benefit from a growing demand for digital dollars.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45788564/bitcoin-bull-run-on-the-brink-as-long-term-holders-accelerate-profit-taking-report">Bitcoin Bull Run On The Brink As Long-Term Holders Accelerate Profit-Taking: Report</a>
At the heart of the company's operations is USDC, a dollar-backed stablecoin increasingly used in digital payments, cross-border transfers, and corporate treasury management. 
That demand has accelerated in 2025, partly fueled by improving regulatory clarity in the U.S. which is expected to strengthen the legitimacy and utility of stablecoins within traditional finance.
A recent report from Deutsche Bank supports this outlook, suggesting stablecoins are nearing mainstream adoption. 
The bank highlighted their role in reinforcing the global dominance of the U.S. dollar and improving efficiency in international finance.
Circle's public listing is seen by some analysts as more than just a tech IPO, it reflects a broader market belief that stablecoins are evolving into foundational tools for the global financial system.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45777944/jpmorgan-to-accept-crypto-linked-etfs-as-loan-collateral">JPMorgan To Accept Crypto-Linked ETFs As Loan Collateral</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$USDC

CRCL

Circle Surges To $69 In NYSE Debut, Raising $1.1B As Investors Bet On Stablecoins Going Mainstream

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $125.

Barrington Research Maintains Outperform on HealthEquity, Raises Price Target to $125

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true</a>

Comments

RLX Technology

RLX Technology (RLX) Opzioni

RLX Technology (NYSE:RLX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO